10-Q: Assembly Biosciences Q1 2026 Results: Pipeline Progress & Gilead Collaboration

Assembly Biosciences reports Q1 2026 financial results, highlighting progress in its viral disease pipeline and ongoing collaboration with Gilead Sciences.

Summary

• Assembly Biosciences, Inc. filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company reported a net loss of $9.1 million for the quarter, compared to a net loss of $8.8 million in the same period of 2025.
• Collaboration revenue from Gilead Sciences was $8.2 million for Q1 2026, a decrease from $9.4 million in Q1 2025.
• Research and development expenses remained stable at $14.9 million, while general and administrative expenses increased slightly to $4.7 million.
• As of March 31, 2026, the company had cash, cash equivalents, and marketable securities totaling $226.6 million, which management believes is sufficient for over one year of operating requirements.
• Gilead Sciences exercised its option to license Assembly's HPI program (ABI-5366 and ABI-1179) in December 2025, resulting in a $35 million payment to Assembly.
• Gilead declined to exercise its option for the 4334 program in March 2026, leaving Assembly to retain full control.
• Phase 2 clinical studies for the HPI program are anticipated to be initiated by Gilead in 2026.
• Phase 2 clinical studies for ABI-6250 are expected to commence in the fourth quarter of 2026.
• ABI-7272 is currently undergoing regulatory filing-enabling studies.
• The company is actively evaluating partnering opportunities for the 4334 program.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with significant pipeline progress and a strong cash position, balanced by continued net losses and a slight decrease in collaboration revenue.

Positives

• Gilead Sciences exercised its option for the HPI program (ABI-5366 and ABI-1179), providing a $35 million payment and advancing these candidates.
• Assembly Biosciences has sufficient cash, cash equivalents, and marketable securities ($226.6 million as of March 31, 2026) to fund operations into 2028.
• Phase 1b data for ABI-5366 showed a 94% reduction in HSV-2 shedding rate and a 94% reduction in lesion rate compared to placebo, exceeding targets.
• Phase 1b data for ABI-1179 showed a 98% reduction in HSV-2 shedding rate and a 91% reduction in lesion rate compared to placebo, exceeding targets.
• Chronic toxicology studies for ABI-5366 and ABI-1179 are complete, supporting advancement to Phase 2.
• Phase 1a study for ABI-6250 demonstrated target engagement (NTCP) and a pharmacokinetic profile supporting once-daily oral dosing, with chronic toxicology studies complete.
• Phase 1b study for ABI-4334 showed antiviral activity and maintained exposures above anticipated levels for potent viral activity and cccDNA inhibition.
• The company is actively seeking partners for the 4334 program, which it retains full control over.

Negatives

• The company reported a net loss of $9.1 million for the quarter, continuing its history of unprofitability.
• Collaboration revenue from Gilead decreased by 13% to $8.2 million compared to the prior year period.
• Gilead declined to exercise its option for the 4334 program, potentially impacting its future development without a partner.
• External program expenses for ABI-5366 decreased significantly by 78% due to trial completion, indicating a shift in focus or resource allocation.
• External program expenses for ABI-6250 decreased by 39% and for ABI-7272 by 60%, suggesting a slowdown or completion of certain study phases.
• The company has no approved products and relies entirely on the success of its pipeline candidates.
• The company will require additional financing to fund future operations and development.

Risks

• The company has no approved products and depends on the future success of its research and development pipeline, with no certainty of regulatory approval or commercialization.
• Assembly Biosciences is not currently profitable and will require additional financing to complete product development and fund future operations.
• The success of the collaboration with Gilead Sciences is critical, and any failure or termination could adversely affect the business.
• Nonclinical and clinical studies are expensive, time-consuming, and may fail to demonstrate the required safety and efficacy for product approval.
• Reliance on contract research organizations (CROs) and other third-party vendors introduces risks related to control, timelines, and data integrity.
• Top-line, preliminary, or interim data may not accurately reflect final study results, and discrepancies could harm the company's reputation and development prospects.
• The company relies on third parties for formulation and manufacturing, increasing the risk of supply shortages or delays.
• Loss of key management personnel could materially harm the business.
• Collaboration partners, including Gilead, might delay, prevent, or undermine the success of product candidates.
• The company may not be successful in establishing and maintaining collaborations, which could hinder the development of certain product candidates.
• The company relies on data provided by third parties that has not been independently verified.
• Research, development, and commercialization goals, including data releases, may not be achieved within estimated timeframes, potentially impacting the stock price.
• Competitors' developments could render product candidates or technologies obsolete or non-competitive.
• Negative clinical data from competitors with similar mechanisms of action could adversely affect perceptions of Assembly's product candidates.
• Disruptions to information technology systems or data security breaches, including cybersecurity incidents, could materially harm the business.
• The company's ability to use net operating loss and credit carryforwards may be limited due to ownership changes.
• Extensive and costly government regulation, and failure to comply, could have a material adverse effect on operations.
• Regulatory approval processes are lengthy, unpredictable, and may result in delays or denial.
• The company and its partners are subject to stringent data privacy and security laws, with non-compliance leading to costs and liabilities.
• The company and its collaborators may be subject to anti-kickback, false claims, and other fraud and abuse laws.
• The company faces the risk of product liability claims and may not be able to obtain adequate insurance.
• Liability claims associated with the use of hazardous materials and chemicals are possible.
• Employee or contractor misconduct could result in significant liability and harm to the company's reputation.
• The company's business depends on protecting its intellectual property, and litigation or infringement could be costly.
• The company may infringe on the intellectual property rights of others, potentially delaying or increasing the cost of commercialization.
• The price of the company's common stock is volatile and could fluctuate significantly, leading to potential investor losses.

Future Outlook

Management believes the company currently has sufficient funds to meet its operating requirements beyond one year from the date of issuance. Future capital requirements will depend on various factors including the success of the Gilead collaboration, development costs, regulatory review outcomes, and manufacturing capabilities. The company expects to continue raising capital as needed.

Management Comments

• Management believes the Company currently has sufficient funds to meet its operating requirements beyond one year from the date these unaudited condensed consolidated financial statements are issued.
• We expect our future operating expenses to increase over the coming years as we continue to expand our pipeline and advance our candidates.
• We expect to continue to raise capital when and as needed and at the time and in the manner most advantageous to us.

Industry Context

StockSavvy.ai notes that Assembly Biosciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on antiviral therapeutics. The company's reliance on collaborations, particularly with a major player like Gilead Sciences, is a common strategy to de-risk development and secure funding. The progress and setbacks in its pipeline candidates, such as the HPI program's advancement under Gilead and the 4334 program's retention by Assembly, reflect the typical challenges and opportunities in drug development.

Comparison to Industry Standards

• Assembly Biosciences' net loss of $9.1 million for the quarter is consistent with many early-stage biotechnology companies that are pre-revenue and heavily invested in R&D.
• The company's cash runway extending into 2028, with $226.6 million in cash, cash equivalents, and marketable securities, is a strong position compared to many smaller biotech firms, providing a buffer for continued development.
• The significant reduction in external program expenses for ABI-5366 (78%) and ABI-6250 (39%) suggests a transition from active clinical trial phases to later-stage development or partnership evaluation, a common industry practice.
• The 13% decrease in collaboration revenue from Gilead, while a negative, is not unusual as specific project milestones or service periods conclude, and the overall value of the collaboration remains significant with the HPI program option exercise.

Legal Proceedings

• The company is not a party to any material legal proceedings.

Related Party Transactions

• Accounts receivable from collaboration with a related party: $451,000 as of March 31, 2026.
• Deferred revenue from a related party: $29,076,000 as of March 31, 2026.
• Collaboration revenue from a related party (Gilead Sciences): $8,213,000 for the three months ended March 31, 2026.

Stakeholder Impact

• Shareholders: The company's continued net losses and reliance on future financing may impact stock price volatility. Positive clinical data and strategic partnerships offer potential upside.
• Employees: Increased headcount and stock-based compensation suggest continued investment in personnel, but future funding needs could impact job security.
• Partners (Gilead Sciences): The exercise of the HPI option by Gilead signifies a positive development for the collaboration, while the decline for 4334 indicates a strategic shift.
• Creditors: As a pre-revenue company, the primary concern for creditors would be the company's ability to meet its obligations, which appears manageable given its cash reserves.

Next Steps

• Gilead is expected to initiate a Phase 2 clinical study for the HPI program in 2026.
• Phase 2 clinical studies for ABI-6250 are expected to commence in the fourth quarter of 2026.
• ABI-7272 is currently undergoing regulatory filing-enabling studies.
• Assembly Biosciences is actively evaluating partnering opportunities for the 4334 program.
• Assembly Biosciences will make a decision regarding the Profit-Share for the HPI program by mid-2026.

Key Dates

Recommendation

Assembly Biosciences presents a mixed picture. The positive clinical data for its HPI candidates (ABI-5366, ABI-1179) and the significant cash runway are strong positives. However, the continued net losses, the decrease in collaboration revenue, and the reliance on future financing and partnerships for other pipeline assets warrant a cautious approach. The company is in a critical development phase, and while potential upside exists, significant risks remain. Therefore, a 'hold' recommendation is appropriate for seasoned investors and institutions, pending further clinical and partnership developments.

Keywords

Assembly Biosciences, SEC Filing, Form 10-Q, Biotechnology, Viral Diseases, Hepatitis B, Hepatitis Delta, Genital Herpes, Gilead Sciences, Clinical Trials, Drug Development, Financial Results, Collaboration Agreement, ABI-5366, ABI-1179, ABI-6250, ABI-4334, ABI-7272